Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
NCT04097145
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Banner University Medical Center Phoenix, Phoenix, Arizona +78 locations
Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
Register for Updates
Multi-Center PAMPA Study
NCT05004727
Recruiting
This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of the proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an interventi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +4 locations
Conditions: Psoriasis
Register for Updates
Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing
NCT05560477
Recruiting
The purpose of this clinical trial is to assess the safety and efficacy of AM3101 to facilitate meniscal repair and reduce the incidence of non-healing complications and morbidities associated with a failed meniscal repair. This is a prospective, randomized, controlled, double-blinded, multi-center study.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
05/27/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Meniscus Tear
Register for Updates
Further MT for Antibiotic-Resistant Bacterial Colonization in Inpatients
NCT05835206
Recruiting
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection. Limited data from prior studies suggest that MT may be an effective treatment to reduce intestinal MDRO colonization Although shedding of MDROs from patients to their surrounding environment is a recognized pathway of transmission, the potential effect of MT on the transmission of MDRO to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia +4 locations
Conditions: Multi-drug Resistant Organism
Register for Updates
The Gut Microbiome and Immunotherapy Response in Solid Cancers
NCT06050733
Recruiting
The aim of this study is characterize the gastrointestinal microbiomes of patient with solid cancer undergoing standard of care treatment with programmed cell death protein 1 (PD-1) /programmed cell death ligand (PD-L1) blockade.
Gender:
ALL
Ages:
Between 35 years and 75 years
Trial Updated:
05/27/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Cancer
Register for Updates
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
NCT06258902
Recruiting
The participants of this study will be of any age who are exposed to at least 1 dose of odevixibat at any time during pregnancy (from 1 day prior to conception to pregnancy outcome) and/or at any time during lactation (up to 12 months of infant age or weaning, whichever comes first. This study will collect data obtained via a variety of sources, including enrolled pregnant or lactating participants, the healthcare providers (HCP) involved in their care or the care of their infants, if applicabl... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
05/27/2025
Locations: Virtual Research Coordination Center Odevixibat (BYLVAY) Pregnancy Surveillance Program, Wilmington, North Carolina
Conditions: Pregnancy Related
Register for Updates
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006
Recruiting
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction (G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Los Angeles Cancer Network, Anaheim, California +63 locations
Conditions: Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Register for Updates
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
NCT06672705
Recruiting
This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some ly... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Register for Updates
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
NCT06846463
Recruiting
This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Register for Updates
A Randomized Controlled Trial Comparing the Efficacy of Commercial Weight Management Programs
NCT06972277
Recruiting
The study compares the effectiveness of three commercial weight management programs. The primary outcome is absolute and percentage weight change at 12-weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: WW International, Inc, New York, New York
Conditions: Obesity and Overweight
Register for Updates
The GBA Multimodal Study in Parkinson's Disease
NCT04101968
Recruiting
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessm... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/27/2025
Locations: Oregon Health & Science University, Portland, Oregon +2 locations
Conditions: Parkinson Disease, GBA Gene Mutation, Gaucher Disease
Register for Updates
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
NCT05044039
Recruiting
While chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier. One potential mechanism of relapse is limited CAR T-cell persistence. Pre-clinical research shows that PI3K inhibition represents an intriguing mechanism for increasing CAR T-cell persistence that is easily reversible and CAR T-cell agnostic. The investigators hypothesize that PI3K inhibition with duvelisib would be safe, may pr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia
Register for Updates